Assyro AI

FDA Orange Book · active-ingredient family

Desloratadine

Desloratadine is approved as 3 brand and 11 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:CLARINEX · NDA 021312

3

Brand (NDA)

11

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · solution, tablet, tablet, orally disintegrating

ProductApplicantApplicationTEApproved
CLARINEXRLD×2ORGANONNDA 021312Jul 14, 2005
CLARINEXRLDORGANON LLCNDA 021300Sep 01, 2004
CLARINEXRLDORGANONNDA 021165ABDec 21, 2001

Generic (ANDA) products (11)

ProductApplicantApplicationTEApproved
DESLORATADINETAROANDA 202936May 26, 2016
DESLORATADINETAROANDA 202592Jun 30, 2015
DESLORATADINEAJENAT PHARMSANDA 078355ABApr 19, 2012
DESLORATADINENATCO PHARMA USAANDA 078351ABFeb 10, 2012
DESLORATADINEPERRIGOANDA 078361Dec 22, 2011
DESLORATADINEDR REDDYS LABS LTDANDA 078365ABMar 08, 2011
DESLORATADINECHARTWELL RXANDA 078364Dec 03, 2010
DESLORATADINESUN PHARM INDSANDA 078359Nov 16, 2010
DESLORATADINELUPIN PHARMSANDA 078352ABOct 25, 2010
DESLORATADINE×2REDDYSANDA 078367Jul 12, 2010
DESLORATADINEORBION PHARMSANDA 078357ABFeb 19, 2010

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Desloratadine — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.